Switzerland· 69243001
Axhidrox 2,2 mg/Hub, Creme
A glycopyrronium product containing glycopyrronium, registered in Switzerland by Gebro Pharma AG and dispensed under Swissmedic category B. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Glycopyrronium is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AA01 (glycopyrronium), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Glycopyrronium · ATC D11AA01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- glycopyrronium
- Manufacturer
- Gebro Pharma AG
- Country
- Switzerland (CH)
- ATC code
- D11AA01
- ATC class
- Glycopyrronium
- Defined daily dose
- 8.8 mg, T
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
108 interactions on record for glycopyrronium.
Graded by severity as the source publishes them — 107 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glycopyrronium · interactions on record
108 records
- 107 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glycopyrronium in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainAXHIDROX 2,2 MG/PULSACION CREMAIndustrial Farmaceutica Cantabria S.A.
- PolandAxhidroxDr. August Wolff GmbH & Co. KG Arzneimittel
- SwedenGlycopyrronium Cantabria 2,2 mg/pumpning KrämIndustrial Farmaceutica Cantabria S.A.
- NetherlandsAxhidrox 8 mg/g, crèmeEuro Registratie Collectief B.V.
- ItalyGLICOPIRRONIO DOCDOC GENERICI S.R.L.
- IcelandEnurev BreezhalerNovartis Europharm Limited*
- United StatesQbrexzaJourney Medical Corporation
- GermanyRybrilaColonis Pharma B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Austria · Rybrila
- Germany · Rybrila
- Spain · Axhidrox
- Sweden · Glycopyrronium Cantabria
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c35dbf6-c642-4282-bc2f-e7326e7ec8c0 GET /v1/drugs/9c35dbf6-c642-4282-bc2f-e7326e7ec8c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about glycopyrronium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.